Literature DB >> 17308139

Ovarian and adrenal hyperandrogenism.

Enrico Carmina1.   

Abstract

Because in normal women androgens are secreted in almost equal quantities by both adrenals and ovaries, for many years many studies have tried to distinguish the source of androgen excess. However, in the last 10-15 years, the diagnoses of ovarian or adrenal hyperandrogenism have almost disappeared. This is due to the lack of specificity of dynamic tests as well as to the emphasis given on clinical information and ovarian sonography for the diagnosis of hyperandrogenic syndromes. However, determination of the source of increased androgens may still be useful for improving the classification and the understanding of androgen excess disorders. The aim of this review is to examine the source of androgen excess in the three more common androgen excess disorders: polycystic ovary syndrome (PCOS), idiopathic hyperandrogenism; and nonclassic 21-hydroxylase deficiency (NCAH). The ovary is the main androgen source in PCOS and idiopathic hyperandrogenism while adrenal androgen secretion is prevalent in NCAH. However, androgen secretion from more than one source is common in all main forms of hyperandrogenism as is the case in 70-80% of patients with NCAH, in 35% of women with PCOS, and in 50% of patients with idiopathic hyperandrogenism. Secondary PCOS is the main cause of ovarian androgen excess in nonclassic 21-hydroxylase deficiency while adrenal hyperandrogenism in PCOS and idiopathic hyperandrogenism is probably the consequence of multiple factors including hyperinsulinemia, altered cortisol metabolism, and increased ovarian steroid production. The clinical image is not generally affected by the source of androgen excess. However, hyperandrogenic patients with increased dehydroepiandrosterone sulfate (DHEAS) tend to have lower body weight and insulin levels and a better metabolic profile.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17308139     DOI: 10.1196/annals.1365.011

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

Review 1.  Adrenal androgens and androgen precursors-definition, synthesis, regulation and physiologic actions.

Authors:  Adina Turcu; Joshua M Smith; Richard Auchus; William E Rainey
Journal:  Compr Physiol       Date:  2014-10       Impact factor: 9.090

2.  Divergent Associations Between Serum Androgens and Ovarian Reserve Markers Revealed in Patients With Polycystic Ovary Syndrome.

Authors:  Youran Li; Yanhong Zhai; Lin Li; Yifan Lu; Shaofei Su; Ying Liu; Zhengwen Xu; Mingwei Xin; Qiaoli Zhang; Zheng Cao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

3.  Metabolic Alteration Analysis of Steroid Hormones in Niemann-Pick Disease Type C Model Cell Using Liquid Chromatography/Tandem Mass Spectrometry.

Authors:  Ai Abe; Masamitsu Maekawa; Toshihiro Sato; Yu Sato; Masaki Kumondai; Hayato Takahashi; Masafumi Kikuchi; Katsumi Higaki; Jiro Ogura; Nariyasu Mano
Journal:  Int J Mol Sci       Date:  2022-04-18       Impact factor: 6.208

4.  An Association Study between INSR/NsiI (rs2059806) and INSR/PmlI (rs1799817) SNPs in Women with Polycystic Ovary Syndrome from West Azerbaijan Province, Iran.

Authors:  Morteza Bagheri; Isa Abdi-Rad; Nima Hosseini-Jazani; Rasoul Zarrin; Fariba Nanbakhsh; Nauman Mohammadzaie
Journal:  J Reprod Infertil       Date:  2015 Apr-Jun

5.  Insulin resistance and endocrine-metabolic abnormalities in polycystic ovarian syndrome: Comparison between obese and non-obese PCOS patients.

Authors:  Parvin Layegh; Zohreh Mousavi; Donya Farrokh Tehrani; Seyed Mohammad Reza Parizadeh; Mohammad Khajedaluee
Journal:  Int J Reprod Biomed (Yazd)       Date:  2016-04

6.  Characteristics and outcomes of in vitro fertilization in different phenotypes of polycystic ovary syndrome.

Authors:  Selçuk Selçuk; Enis Özkaya; Ahmet Eser; Melda Kuyucu; Hüseyin Tayfun Kutlu; Belgin Devranoğlu; Kenan Sofuoğlu; Vedat Erkan Dayıcıoğlu
Journal:  Turk J Obstet Gynecol       Date:  2016-03-10

Review 7.  Polycystic Ovary Syndrome: A Disorder of Reproductive Age, Its Pathogenesis, and a Discussion on the Emerging Role of Herbal Remedies.

Authors:  Ling-Hui Zeng; Saba Rana; Liaqat Hussain; Muhammad Asif; Malik Hassan Mehmood; Imran Imran; Anam Younas; Amina Mahdy; Fakhria A Al-Joufi; Shaymaa Najm Abed
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

8.  Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome.

Authors:  Jacob E Pruett; Edgar D Torres Fernandez; Steven J Everman; Ruth M Vinson; Kacey Davenport; Madelyn K Logan; Stephanie A Ye; Damian G Romero; Licy L Yanes Cardozo
Journal:  Int J Mol Sci       Date:  2021-03-04       Impact factor: 5.923

9.  Simultaneous quantitation of four androgens and 17-hydroxyprogesterone in polycystic ovarian syndrome patients by LC-MS/MS.

Authors:  Zheng Cao; Yifan Lu; Yuting Cong; Ying Liu; Youran Li; Husheng Wang; Qiaoli Zhang; Wenxi Huang; Jingrui Liu; Ying Dong; Guodong Tang; Yiqi R Luo; Chenghong Yin; Yanhong Zhai
Journal:  J Clin Lab Anal       Date:  2020-08-21       Impact factor: 3.124

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.